Discussion
dysphagia, SSCC, tumor, toxicity, toxicities
DYSPHAGIA, TUMOR, ADVERSE EVENT
Currently, the standard of care for small SSCC is radiotherapy, which is highly effective on locoregional tumor control but can be associated with late adverse event and toxicity such as dysphagia.Since the development of new trans-oral technique and especially TORS, functional results are encouraging, but because of the lack of hindsight with this emerging technique, a critical analysis needs to be performed before supporting a change in the treatment strategy.It is therefore imperative to develop treatment strategies that optimize the functional outcomes and QoL of these patients. In the current literature, no prospective head-to-head trials are available to compare objectively these two issues.So, the main objective of this research is to assess and compare objectively and prospectively the efficacy of these therapeutic approaches in early SSCC patients according to 4 classes of outcomes; quality of life, oncological, functional and economic resources.Regarding QoL questionnaires, the MDADI and the EORTC H1N43 will allow to specifically assess dysphagia and to compare our results with those of the current literature.The CTC-AE toxicity questionnaire will be evaluated by the physician to objectively report on the early and late toxicities.The impact on the global QoL is evaluated with the EORTC QLQ-C30 questionnaire.Finally, the EQ-5D-5L QoL questionnaire is used to make a link between the QoL outcomes by calculating the utilities, and also QALYs, and the associated costs (the different QoL questionnaires and their advantages are summarized in Fig. QoL questionnaires comparison